行情

TTNP

TTNP

Titan制药
NASDAQ

实时行情|Nasdaq Last Sale

0.9296
-0.0604
-6.10%
已收盘, 16:00 01/21 EST
开盘
1.000
昨收
0.9900
最高
1.000
最低
0.9134
成交量
15.67万
成交额
--
52周最高
4.610
52周最低
0.9134
市值
921.62万
市盈率(TTM)
1.821
分时
5日
1月
3月
1年
5年
TTNP, ISIG and IINN among pre market gainers
Nutriband (NASDAQ:NTRB) +36% issued full patent from the Korean intellectual property office for its "abuse and misuse deterrent transdermal system" application. Medalist Diversified (NASDAQ:MDRR) +27% approves share buyback program. Xeris Biopharma Holdin...
Seekingalpha · 2021/12/31 13:20
Titan Pharma to evaluate strategic alternatives
Titan Pharmaceuticals (NASDAQ:TTNP) has gained ~15.0% in the pre-market after announcing it has started a process to evaluate strategic alternatives to improve shareholder value. The pharmaceutical developer has selected Maxim Group LLC
Seekingalpha · 2021/12/21 13:32
RIOT, MARA and ASXC among pre market gainers
Reliance Global (NASDAQ:RELI) +85%. Aridis Pharmaceuticals (NASDAQ:ARDS) +72% after its antibody cocktail retains effectiveness against Omicron variant. Quoin Pharmaceuticals (NASDAQ:QNRX) +44%. Cassava Sciences (NASDAQ:SAVA) +40% Cassava Sciences, Biofron...
Seekingalpha · 2021/12/21 13:23
BRIEF-Titan Pharmaceuticals To Explore Strategic Alternatives
reuters.com · 2021/12/21 13:14
Titan Pharma To Explore Strategic Alternatives
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Titan
Benzinga · 2021/12/21 13:03
Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, in a presentation given today at the Society for Neuroscience 2021 Meeting, Ben Land, Ph.D., Research Assistant Professor at the University of Washington's Department of ...
PR Newswire · 2021/11/08 21:15
FRSX、IBN 和 TTNP 是上市前的赢家
Remark Holdings (NASDAQ:MARK) +266%. Sonim Technologies (NASDAQ:SONM) +96%. Creatd CRTD +69% announces second NFT drop, includes photographs of former President Donald Trump PAE Incorporated PAE +67% Amentum to buy PAE in an all-cash deal
Seekingalpha · 2021/10/25 12:32
Titan Pharmaceuticals 获得资金用于为发展中国家的妇女开发 HIV 联合治疗和避孕植入物
Titan Pharmaceuticals, Inc.
Benzinga · 2021/10/25 11:17
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解TTNP最新的财务预测,通过TTNP每股收益,每股净资产,每股现金流等数据分析Titan制药近期的经营情况,然后做出明智的投资选择。
分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测TTNP价格均价为7.00,最高价位7.00,最低价为7.00。
最高7.00
均价7.00
最低7.00
现价0.9296
EPS
实际EPS
预期EPS
-1.06-0.80-0.53-0.27
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 40
机构持股: 46.46万
持股比例: 4.69%
总股本: 991.42万
类型机构数股数
增持
3
3,359
建仓
4
1.30万
减持
5
8.41万
平仓
4
12.66万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.92%
制药与医学研究
-1.11%
高管信息
Chairman/Executive Director
Marc Rubin
President/Chief Operating Officer/Director
Katherine DeVarney
Independent Director
Joseph Akers
Independent Director
M. David MacFarlane
Independent Director
James McNab
Independent Director
Scott Smith
暂无数据
TTNP 简况
Titan Pharmaceuticals Inc(Titan)是一家专业制药公司。该公司从事医学疾病疗法的开发和医药产品的开发。该公司的产品开发计划利用其长期给药平台 ProNeura。该公司的产品Probuphine植入物基于ProNeura技术,用于临床稳定患者阿片类药物使用障碍的维持治疗。该公司的ProNeura连续给药系统由一种由乙烯-醋酸乙烯酯(EVA)和药物混合物制成的小型实心棒组成。该公司开发两个产品项目,即Kappa阿片类激动剂肽项目和纳美芬开发项目。该公司的Kappa阿片类激动剂肽(TP-2021)使用ProNeura技术为某些疼痛提供非成瘾性治疗。

微牛提供Titan Pharmaceuticals, Inc.(NASDAQ-TTNP)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的TTNP股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易TTNP股票基本功能。